Call to Caution with the Use of Atypical Antipsychotics for Treatment of Depression in Older Adults
Abstract
:1. Introduction
2. Depression and the Use of Antipsychotics in Older Adults
2.1. Treatment-Resistant Depression among Older Adults
2.2. Use of the Atypical Antipsychotics in the Management of Depression in Older Adults
2.3. Drug-Induced Parkinsonism with Use of Atypical Antipsychotics in Older Adults
2.4. Depression in Idiopathic Parkinson Disease and Management
2.5. Antipsychotic Use May Unmask Idiopathic Parkinson Disease
3. Conclusions
Acknowledgments
Author Contributions
Conflicts of Interest
References
- Whiteford, H.A.; Degenhardt, L.; Rhem, J.; Baxter, A.J.; Ferrari, A.J.; Erskine, H.E.; Charlson, F.J.; Norman, R.E.; Flaxman, A.D.; Johns, N.; et al. Global burden of disease attributable to mental and substance use disorders: Findings from the Global burden of Disease Study 2010. Lancet 2013, 328, 1575–1586. [Google Scholar] [CrossRef]
- Allard, P.; Gram, L.; Timdahl, K.; Behnke, K.; Hanson, M.; Sogaard, J. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: A double-blind, randomised 6-month comparative trial with citalopram. Int. J. Geriatr. Psychiatry 2004, 19, 1123–1130. [Google Scholar] [CrossRef] [PubMed]
- Schatzberg, A.; Roose, S. A double-blind.; placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am. J. Geriatr. Psychiatry 2006, 14, 361–370. [Google Scholar] [CrossRef] [PubMed]
- Lenze, E.J.; Mulsant, B.H.; Blumberger, D.M.; Karp, J.F.; Newcomer, J.W.; Anderson, S.J.; Dew, M.A.; Butters, M.A.; Stack, J.A.; Begley, A.E.; et al. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late-life: A randomized, double-blind, placebo-controlled trial. Lancet 2015, 38, 2404–2412. [Google Scholar] [CrossRef]
- Steffens, D.C.; Nelson, J.C.; Eudicone, J.M.; Andersson, C.; Yang, H.; Tran, Q.V.; Forbes, R.A.; Carlson, B.X.; Berman, R.M. Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: A pooled subpopulation analysis. Int. J. Geriatr. Psychiatry 2011, 26, 564–572. [Google Scholar] [CrossRef] [PubMed]
- Sheffrin, M.; Driscoll, H.C.; Lenze, E.J.; Mulsant, B.H.; Pollock, B.G.; Miller, M.D.; Butters, M.A.; Dew, M.A.; Reynolds, C.F. Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: Getting to remission. J. Clin. Psychiatry 2009, 70, 208–213. [Google Scholar] [CrossRef] [PubMed]
- Rutherford, B.; Sneed, J.; Miyazaki, M.; Eisenstadt, R.; Devanand, D.; Sackeim, H.; Roose, S. An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression. Int. J. Geriatr. Psychiatry 2007, 22, 986–991. [Google Scholar] [CrossRef] [PubMed]
- Gentile, S. Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder. J. Clin. Psychopharmacol. 2007, 27, 35–45. [Google Scholar] [CrossRef] [PubMed]
- Coplan, J.; Grugger, J.J.; Tasleem, H. Tardive dyskinesia from atypical antipsychotic agents in patients with mood disorders in a clinical setting. J. Affect. Disord. 2013, 50, 868–871. [Google Scholar] [CrossRef] [PubMed]
- Erro, R.; Bhatia, K.P.; Tinazzi, M. Parkinsonism Following Neuroleptic Exposure: A Double Hit Hypothesis? Mov. Disord. 2001, 30, 780–785. [Google Scholar] [CrossRef] [PubMed]
- Foubert-Samier, A.; Helmer, C.; Perez, F.; Le Goff, M.; Auriacombe, S.; Elbaz, A.; Dartigues, J.F.; Tison, F. Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort. Neurology 2012, 79, 1615–1621. [Google Scholar] [CrossRef] [PubMed]
- Cummings, J.L. Depression and Parkinson’s disease: A review. Am. J. Psychiatry 1992, 149, 443–454. [Google Scholar] [PubMed]
- Slaughter, J.R.; Slaughter, K.A.; Nichols, D.; Holmes, S.E.; Martens, M.P. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson’s disease. J. Neuropsychiat. Clin. Neurosci. 2001, 13, 187–196. [Google Scholar] [CrossRef] [PubMed]
- Goldman, J.G.; Postuma, R. Premotor and Non-motor features of Parkinson’s disease. Curr. Opin. Neurol. 2014, 27, 434–441. [Google Scholar] [CrossRef] [PubMed]
- Mojtabai, R.; Olfosn, M. Major depression in community-dwelling middle-aged and older adults: Prevalence and 2- and 4-year follow-up symptoms. Psychol. Med. 2004, 34, 623–634. [Google Scholar] [CrossRef] [PubMed]
- Byers, A.L.; Yaffe, K.; Covinsky, K.E.; Friedman, M.B.; Bruce, M.L. High Occurrence of Mood and Anxiety Disorders Among Older Adults: The National Comorbidity Survey Replication. Arch. Gen. Psychiatry 2010, 67, 489–496. [Google Scholar] [CrossRef] [PubMed]
- Goff, D.C.; Jenike, M.A. Treatment- Resistant Depression in the Elderly. J. Am. Geriatr. Soc. 1986, 34, 63–70. [Google Scholar] [CrossRef] [PubMed]
- Kok, R.M.; Heeren, T.J.; Nolen, W.A. Continuing Treatment of Depression in Elderly: A Systematic Review and Meta-Analysis of Double-Blinded Randomized Controlled Trials With Antidepressants. Am. J. Geriatr. Psychiatry 2011, 19, 249–255. [Google Scholar] [CrossRef] [PubMed]
- Nelson, J.C.; Delucchi, K.; Schneider, L. Efficacy of Second Generation Antidepressants in Late-Life Depression: A Meta-Analysis of the Evidence. Am. J. Geriatr. Psychiatry 2008, 16, 558–567. [Google Scholar] [CrossRef] [PubMed]
- White, E.M.; Basinski, J.; Farhi, P.; Dew, M.A.; Begley, A.; Mulsant, B.H.; Reynolds, C.F. Geriatric Depression Treatment in Nonresponders to Selective Serotonin Reuptake Inhibitors. J. Clin. Psychiatry 2004, 65, 1634–1641. [Google Scholar] [CrossRef]
- Fava, M. Diagnosis and definition of treatment-resistant depression. Biol. Psychiatry 2003, 53, 649–659. [Google Scholar] [CrossRef]
- Birrer, R.B.; Vemuri, S.P. Depression in Later Life: A Diagnostic and Therapeutic Challenge. Am. Fam. Physician 2004, 69, 2375–2382. [Google Scholar] [PubMed]
- Ganzini, L.; Smith, D.M.; Fenn, D.S.; Lee, M.A. Depression and mortality in medically ill older adults. J. Am. Geriatr. Soc. 1997, 45, 307–312. [Google Scholar] [CrossRef] [PubMed]
- Callahan, C.M.; Dittus, R.S.; Rierney, W.M. Primary care physicians’ medical decision making for late-life depression. J. Gen. Int. Med. 1996, 11, 218–225. [Google Scholar] [CrossRef]
- Boswell, E.B.; Stoudemire, A. Major depression in the primary care setting. Am. J. Med. 1996, 101, 3S–9S. [Google Scholar] [CrossRef]
- Maher, A.R.; Theodore, G. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. J. Manag. Care Pharm. 2012, 18 (5 Suppl. B), 1–20. [Google Scholar] [CrossRef]
- Maher, A.R.; Maglione, M.; Bagley, S.; Suttorp, M.; Hu, J.H.; Ewing, B.; Wang, Z.; Timmer, M.; Sultzer, D.; Shekelle, P.G. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in Adults: A systematic review and meta-analysis. JAMA 2011, 306, 1359–1369. [Google Scholar] [CrossRef] [PubMed]
- Trivedi, M.H.; Thase, M.E.; Fava, M.; Nelson, C.J.; Yang, H.; Qi, Y.; Tran, Q.V.; Pikalov, A.; Carlson, B.X.; Marcus, R.N.; et al. Adjunctive aripiprazole in major depressive disorder: Analysis of efficacy and safety in patients with anxious and atypical features. J. Clin. Psychiatry 2008, 69, 1928–1936. [Google Scholar] [CrossRef] [PubMed]
- Jon, D.I.; Kim, D.H.; Seo, H.J.; Kwon, Y.J.; Kim, M.D.; Yang, J.C.; Suh, H.S.; Min, K.J.; Pae, C.U.; Bahk, W.M. Augmentation of aripiprazole for depressed patients with inadequate response to antidepressant treatment: A 6-week prospective, open-label multicenter study. Clin. Neuropharmacol. 2013, 26, 157–161. [Google Scholar] [CrossRef] [PubMed]
- Berman, R.M.; Marcus, R.N.; Swanink, R.; McQuade, R.D.; Carson, W.H.; Corey-Lisle, P.K.; Khan, A. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter. randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 2007, 68, 843–853. [Google Scholar] [CrossRef] [PubMed]
- Marcus, R.N.; McQuade, R.D.; Carson, W.H.; Hennicken, D.; Fava, M.; Simon, J.S.; Trivedi, M.H.; Thase, M.E.; Berman, R.M. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 2008, 28, 156–165. [Google Scholar] [CrossRef] [PubMed]
- Bauer, M.; Dell’osso, L.; Kasper, S.; Pitchot, W.; Dencker Vansvik, E.; Köhler, J.; Jørgensen, L.; Montgomery, S.A. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. J. Affective Disord. 2013, 151, 209–219. [Google Scholar] [CrossRef] [PubMed]
- Anderson, I.M.; Sarsfield, A.; Haddad, P.M. Efficacy, safety and tolerability of quetiapine augmentation in treatment resistant depression: An open-label, pilot study. J. Affective Disord. 2009, 117, 116–119. [Google Scholar] [CrossRef] [PubMed]
- El-Khalili, N.; Joyce, M.; McGill, I.; Buynak, R.J.; Datto, C.; Lindgren, P.; Eriksson, H. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: A multicenter, randomize, double-blind, placebo-controlled study. Int. J. Neuropsychopharmacol. 2010, 13, 917–932. [Google Scholar] [CrossRef] [PubMed]
- Reeves, K.; Batra, S.; May, R.S.; Zhang, R.; Dahl, D.C.; Li, X. Efficacy of risperidone augementation to antidepressants in the management of suicidality in major depressive disorder: A randomized, double-blind, placebo-controlled pilot study. J. Clin. Psychiatry 2008, 69, 1228–1236. [Google Scholar] [CrossRef] [PubMed]
- Papakostas, G.I.; Peterson, T.J.; Nierenberg, A.A.; Murakami, J.L.; Alpert, J.E.; Rosenbaum, J.F.; Fava, M. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant majordepressivedisorder. J. Clin. Psychiatry 2004, 65, 217–221. [Google Scholar] [CrossRef] [PubMed]
- Schmedt, N.; Kollhorst, B.; Enders, D.; Jobski, K.; Krappweis, J.; Garbe, E.; Schink, T. Comparative risk of death in older adults treated with antipsychotics: A population-based cohort study. Eur. Neuropsychopharmacol. 2016, 26, 1390–1400. [Google Scholar] [CrossRef] [PubMed]
- Hulschof, T.A.; Zuidema, S.U.; Ostelo, R.W.; Luijendijk, H.J. The Mortality Risk of Conventional Antipsychotics in Elderly patients: A systematic review and meta-analysis of randomized placebo-controlled trials. J. Am. Med. Dir. Assoc. 2015, 16, 817–824. [Google Scholar] [CrossRef] [PubMed]
- Piersanti, M.; Capannolo, M.; Turchetti, M.; Serroni, N.; De Berardis, D.; Evangelista, P.; Costantini, P.; Orsini, A.; Rossi, A.; Maggio, R. Increase in mortality rate in patients with dementia treated with atypical antipsychotics: A cohort in outpatients in Central Italy. Riv. Psichiatr. 2014, 49, 34–40. [Google Scholar] [PubMed]
- Orsolini, L.; Tomasetti, C.; Valchera, A.; Vecchiotti, A.; Matarazzo, I.; Vellante, F.; Iasevoli, F.; Buonaguro, E.F.; Fornaro, M.; Fiengo, A.L.; et al. An update of safety of clinically used atypical antipsychotics. Exp. Opin. Drug Saf. 2016, 15, 1329–1347. [Google Scholar] [CrossRef] [PubMed]
- Cooper, C.; Katona, C.; Lyketsos, K.; Blazer, D.; Brodaty, H.; Rabins, P.; de Mendonça Lima, C.A.; Livingston, G. A systematic review of treatments for refractory depression in older people. Am. J. Psychiatry 2011, 168, 681–688. [Google Scholar] [CrossRef] [PubMed]
- Miller, L.G.; Jankovic, J. Neurologic approach to drug-induced movement disorders: A study of 135 patients. South Med. J. 1990, 83, 525–532. [Google Scholar] [CrossRef] [PubMed]
- Monstastuc, J.L.; Llau, M.E.; Rscol, O.; Senard, J.M. Drug-induced parkinsonism: A review. Fundam. Clin. Pharmacol. 1994, 8, 293–306. [Google Scholar] [CrossRef]
- Sethi, K.D. Movement disorders induced by dopamine blocking agents. Semin. Neurol. 2001, 21, 59–68. [Google Scholar] [CrossRef] [PubMed]
- Shin, H.W.; Chung, S.J. Drug-Induced Parkinsonism. J. Clin. Neurol. 2012, 8, 15–21. [Google Scholar] [CrossRef] [PubMed]
- Hansen, T.E.; Brown, W.L.; Weigel, R.M.; Casey, D.E. Risk factors for drug-induced parkinsonism in tardive dyskinesia patients. J. Clin. Psychiatry 1988, 49, 139–141. [Google Scholar] [PubMed]
- Noyes, K.; Liu, H.; Holloway, R.G. What is the risk of developing parkinsonism following neuroleptic use? Neurology 2006, 66, 941–943. [Google Scholar] [CrossRef] [PubMed]
- Rochen, P.A.; Stukel, T.A.; Sykora, K.; Gill, S.; Garfinkel, S.; Anderson, G.M.; Normand, S.L.; Mamdani, M.; Lee, P.E.; Li, P.; et al. Atypical Antipsychotics and Parkinsonism. Arch. Int. Med. 2005, 165, 1882–1888. [Google Scholar] [CrossRef] [PubMed]
- Katila, H.; Mezhebovsky, I.; Mulroy, A.; Berggren, L.; Eriksson, H.; Earley, W.; Datto, C. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am. J. Geriatr. Psychiatry 2013, 21, 769–784. [Google Scholar] [CrossRef] [PubMed]
- Parkinson, J. An Essay on the Shaking Palsy. J. Neuropsychiatr. Clin. Neurosci. 2002, 14, 223–236. [Google Scholar] [CrossRef] [PubMed]
- Arsland, D.; Pahlhagen, S.; Ballard, C.G.; Ehrt, U.; Svenningsson, P. Depression in Parkinson disease. Epidemiology, mechanisms, and management. Nat. Rev. Neurol. 2012, 8, 35–47. [Google Scholar] [CrossRef] [PubMed]
- McDonald, W.M.; Richard, I.H.; DeLong, M.R. Prevalence, etiology, and treatment of depression in Parkinson’s disease. Biol. Psychiatry 2003, 54, 363–375. [Google Scholar] [CrossRef]
- Rojo, A.; Aguilar, M.; Garolera, M.T.; Cubo, E.; Navas, I.; Quintana, S. Depression in Parkinson’s disease: Clinical correlates and outcome. Parkinsonism Relat. Disord. 2003, 10, 23–28. [Google Scholar] [CrossRef]
- Arun, M.P.; Bharath, S.; Pal, P.K.; Singh, G. Relationship of depression, disability, and quality of life in Parkinson’s disease: A hospital- based case-control study. Neurol. India 2011, 59, 185–189. [Google Scholar] [PubMed]
- Shiba, M.; Bower, J.H.; Maraganore, D.M.; McDonnell, S.K.; Peterson, B.J.; Ahlskog, J.E.; Schaid, D.J.; Rocca, W.A. Anxiety disorders and depressive disorders preceeding Parkinson’s disease: A case control study. Mov. Disord. 2000, 15, 669–677. [Google Scholar] [CrossRef]
- Shrag, A.; Horsfall, L.; Walters, K.; Noyce, A.; Peterson, I. Prediagnostic presentations of Parkinson’s disease in primary care: A case-control study. Lancet Neurol. 2014, 14, 57–64. [Google Scholar] [CrossRef]
- Rickards, H. Depression in neurological disorders: Parkinson’s disease, multiple sclerosis, and stroke. J. Neurol. Neurosurg. Psychiatry 2005, 76, 48–52. [Google Scholar] [CrossRef] [PubMed]
- Lemke, M.R. Depression in Parkinson’s Disease: Clinical Features and Treatment. Focus Parkinson’s Dis. 2003, 15, 3–8. [Google Scholar] [CrossRef]
- Arsh, L. Depression and Parkinson’s Disease: Current Knowledge. Curr. Neurol. Neurosci. Rep. 2013, 13, 409. [Google Scholar]
- Nuti, A.; Ceravolo, R.; Piccinni, A.; Dell’Agnello, G.; Bellini, G.; Gambaccini, G.; Rossi, C.; Logi, C.; Dell’Osso, L.; Bonuccelli, U. Psychiatric comorbidity in a population of Parkinson’s disease patients. Eur. J. Neurol. 2004, 11, 315–320. [Google Scholar] [CrossRef] [PubMed]
- Richard, I.H. Anxiety disorders in Parkinson’s disease. Adv. Neurol. 2005, 96, 42–55. [Google Scholar] [PubMed]
- Richard, I.H.; McDermott, M.P.; Kurlan, R.; Lyness, J.M.; Como, P.G.; Pearson, N.; Factor, S.A.; Juncos, J.; Serrano Ramos, C.; Brodsky, M.; et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012, 78, 1229–1236. [Google Scholar] [CrossRef] [PubMed]
- Serrano, A.; Menendez, J.; Casarejos, M.J.; Solano, R.M.; Gallego, E.; Sánchez, M.; Mena, M.A.; García de Yebenes, J. Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice. Neuropharmacology 2005, 49, 208–219. [Google Scholar] [CrossRef] [PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Amodeo, K.; Schneider, R.B.; Hegeman Richard, I. Call to Caution with the Use of Atypical Antipsychotics for Treatment of Depression in Older Adults. Geriatrics 2016, 1, 33. https://doi.org/10.3390/geriatrics1040033
Amodeo K, Schneider RB, Hegeman Richard I. Call to Caution with the Use of Atypical Antipsychotics for Treatment of Depression in Older Adults. Geriatrics. 2016; 1(4):33. https://doi.org/10.3390/geriatrics1040033
Chicago/Turabian StyleAmodeo, Katherine, Ruth B. Schneider, and Irene Hegeman Richard. 2016. "Call to Caution with the Use of Atypical Antipsychotics for Treatment of Depression in Older Adults" Geriatrics 1, no. 4: 33. https://doi.org/10.3390/geriatrics1040033
APA StyleAmodeo, K., Schneider, R. B., & Hegeman Richard, I. (2016). Call to Caution with the Use of Atypical Antipsychotics for Treatment of Depression in Older Adults. Geriatrics, 1(4), 33. https://doi.org/10.3390/geriatrics1040033